I think a few posters need to actual read the company ASX...

I think a few posters need to actual read the company ASX releases and listen to what is being said in the webinars.

Some obviously missed comments:

• There is no intent to partner on OA before we have top-line for PAR_008 at a minimum. The new CEO in being carefully selected with the requisite background and experience necessary to assist in the engagement at the right level before any proposed deal is made. The guiding principal set here is to maximize long term (versus short term) value.
• MPS may come earlier that the above
• Most of the big pharma outsource some API manufacturing lines. Hence they already have systems in place to manage and deal indirectly with the manufacturing process itself.